|
|
| | Delgocitinib Basic information |
| Product Name: | Delgocitinib | | Synonyms: | Delgocitinib;JTE052;JTE-052;LEO 124249;LEO124249;3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- 1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile;1,6-Diazaspiro[3.4]octane-1-propanenitrile, 3-methyl-β-oxo-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-, (3S,4R)-;Corectim（Delgocitinib） | | CAS: | 1263774-59-9 | | MF: | C16H18N6O | | MW: | 310.35 | | EINECS: | | | Product Categories: | | | Mol File: | 1263774-59-9.mol |  |
| | Delgocitinib Chemical Properties |
| density | 1.41±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:58.0(Max Conc. mg/mL);186.89(Max Conc. mM) | | pka | -0.65±0.40(Predicted) |
| | Delgocitinib Usage And Synthesis |
| Definition | ChEBI: Delgocitinib is a pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine substituted by a (3S,4R)-1-(cyanoacetyl)-3-methyl-1,6-diazaspiro[3.4]octan-6-yl group at position 4. It is a pan-Janus kinase (JAK) inhibitor and is approved for treatment of atopic dermatitis (AD) in Japan. It has a role as an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor, an anti-inflammatory drug, an antipsoriatic and an antiseborrheic. It is a pyrrolopyrimidine, a tertiary amino compound, a nitrile, an azaspiro compound, a tertiary carboxamide and a N-acylazetidine. |
| | Delgocitinib Preparation Products And Raw materials |
|